JP2025514288A5 - - Google Patents
Info
- Publication number
- JP2025514288A5 JP2025514288A5 JP2024563536A JP2024563536A JP2025514288A5 JP 2025514288 A5 JP2025514288 A5 JP 2025514288A5 JP 2024563536 A JP2024563536 A JP 2024563536A JP 2024563536 A JP2024563536 A JP 2024563536A JP 2025514288 A5 JP2025514288 A5 JP 2025514288A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- amino acid
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20220100348 | 2022-04-27 | ||
| GR20220100348 | 2022-04-27 | ||
| PCT/US2023/066299 WO2023212646A2 (en) | 2022-04-27 | 2023-04-27 | Mutant and mislocalized cell surface nucleophosmin 1 as a diagnostic and therapeutic target of human disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025514288A JP2025514288A (ja) | 2025-05-02 |
| JP2025514288A5 true JP2025514288A5 (enExample) | 2026-05-11 |
Family
ID=88519861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024563536A Pending JP2025514288A (ja) | 2022-04-27 | 2023-04-27 | ヒト疾患の診断および治療標的としての突然変異体および誤局在細胞表面ヌクレオフォスミン１ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250313647A1 (enExample) |
| EP (1) | EP4514858A2 (enExample) |
| JP (1) | JP2025514288A (enExample) |
| CN (1) | CN119487077A (enExample) |
| WO (1) | WO2023212646A2 (enExample) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11896619B2 (en) * | 2020-03-10 | 2024-02-13 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
-
2023
- 2023-04-27 JP JP2024563536A patent/JP2025514288A/ja active Pending
- 2023-04-27 CN CN202380050132.2A patent/CN119487077A/zh active Pending
- 2023-04-27 EP EP23797543.8A patent/EP4514858A2/en active Pending
- 2023-04-27 US US18/860,335 patent/US20250313647A1/en active Pending
- 2023-04-27 WO PCT/US2023/066299 patent/WO2023212646A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220306759A1 (en) | Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof | |
| US11739158B2 (en) | Antibody binding specifically to MUC1 and use thereof | |
| CA2759733C (en) | Anti-human ror1 antibodies | |
| CA2529496C (en) | Anti-cd74 immunoconjugates and methods | |
| US20180303952A1 (en) | Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof | |
| RU2427590C2 (ru) | Анти-mn антитела и способы их применения | |
| JP2024150445A5 (enExample) | ||
| CN113784987B (zh) | 靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法 | |
| CA2996205A1 (en) | Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use | |
| HRP20161029T1 (hr) | Protutijela anti-cd79b i imunokonjugati kao i postupci njihove uporabe | |
| JP2006502699A5 (enExample) | ||
| JP2023508277A5 (enExample) | ||
| CA3066953A1 (en) | Human monoclonal antibodies specific for cd33 and methods of their use | |
| JP2023536631A5 (enExample) | ||
| AU2015252014B2 (en) | Anti-human ror1 antibodies | |
| JP2025514287A5 (enExample) | ||
| CA2582937A1 (en) | Formulation of multivalent antibody constructs and use of same for cancer therapy | |
| JP2023536630A5 (enExample) | ||
| CN118632871A (zh) | 抗vista抗体及其用途 | |
| WO2023212725A2 (en) | Antibody compounds with reactive cysteine and related antibody drug conjugates | |
| RU2025125106A (ru) | Антитела к her3/muc1 и их применения | |
| RU2025121934A (ru) | Анти-egfr/muc1 антитела и их применение | |
| Hamblett | Optimization of pretargeted radioimmunotherapy | |
| CN101277977A (zh) | 癌性疾病调节抗体 |